Figure. Kaplan-Meier (KM) Estimates of Recurrence-Free Survival, Event-Free Survival, and Overall Survival at 5 Years.

Group 1 is talimogene laherparepvec (T-VEC) plus surgery, and group 2 is surgery alone. The vertical marks indicate patients who were censored. Time 0 is the time of randomization. HR indicates hazard ratio. A, Recurrence-free survival was defined as the time from randomization to the first of local, regional, or distant recurrence or death, where patients who withdrew before surgery were imputed as events at baseline. In this analysis, R1 and R2 resections were imputed as events at baseline. Patients without an event were censored at their last evaluable tumor assessment. B, Event-free survival was defined as the time from randomization to the first of local, regional, or distant recurrence after surgery; disease progression that precludes surgery; or death from any cause, whichever occurred first. Patients without an event were censored at their last evaluable tumor assessment. Patients with no evaluable tumor assessment were censored at surgery date if they had an R0 surgical outcome or on the randomization date if they had a non-R0 surgical outcome. Patients with a nonmelanoma tumor or a second malignant tumor identified before or at surgery were censored at the day after randomization. C, Overall survival was defined as the time from randomization to the date of death from any cause.